| |
|
Product Name:
|
Δcts2/Δard1/Δcts3
|
|
Manufacturer:
|
University of Toledo, Toledo, Ohio and California State
University, Bakersfield Foundation, Bakersfield, California
|
|
Taxonomy:
|
Classification: Mitosporic Onygenales, Coccidioides
Species: Coccidioides posadasii
Strain/Isolate: Δcts2/Δard1/Δcts3
|
|
Additional Information:
|
C. posadasii is a pathogenic fungus that, along with C. immitis, can result in mild to fatal respiratory disease (coccidioidomycosis, San Joaquin Valley fever, desert rheumatism) due
to inhalation of spores in both immunocompetent and immunocompromised individuals. C. posadasii resides in soil in parts of southwestern United States, northern Mexico, and
other areas in South and Central America unlike C. immitis which is primarliy found in California.
|
|
Material Provided:
|
Each vial of NR-166 contains approximately 1 mL of fungal culture containing 10% DMSO.
|
|
Packing/Storage:
|
NR-166 was packaged aseptically in cryovials and is provided frozen on dry ice. The product should be stored at -70°C or colder.
|
|
Growth Conditions:
|
Media:
GYE (1% glucose, 0.5% yeast extract) broth or agar. Note: The addition of 100 mM KCl may enhance growth as the culture is osmotically fragile. This strain is resistant to hygromycin. Addition of hygromycin is optional as the insertion of the gene into the genome is considered a stable insertion. Hygromycin can be added to a final concentration of 75 ug/mL, if desired.
Incubation:
Temperature: 27°C to 35°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use; thaw rapidly.
2. Transfer the entire thawed aliquot into GYE broth.
3. Incubate with shaking at 27°C to 35°C for 2 days. Growth in the presence of hygromycin may take 4-7 days.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
|
Patents or other restrictions:
|
NR-166 is claimed in U.S. Patent Number 7,332,324 and the continuations, continuations-in-part, re-issues and foreign counterparts thereof.
|
References:
|
1. Xue, J., et al. “A Genetically Engineered Live Attenuated Vaccine of Coccidioides posadasii Protects BALB/c Mice against Coccidioidomycosis.” Infect. Immun. 77 (2009): 3196-3208. PubMed:
19487479.
2. Hector, R. and G. W. Rutherford. “The Public Health Need and Present Status of a Vaccine for the Prevention of Coccidioidomycosis.” Ann. N. Y. Acad. Sci. 1111 (2007): 259-268. PubMed: 17344529.
3. Cole, G. T., et al. “A Vaccine against Coccidioidomycosis is Justified and Attainable.” Med. Mycol. 42 (2004): 189-216. PubMed: 15283234.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Coccidioides posadasii, Δcts2/Δard1/Δcts3, NR-166."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|